Regulatory Exclusivity: PEDIATRIC EXCLUSIVITY
✉ Email this page to a colleague
Drugs with Pediatric Exclusivity Regulatory Exclusivity
Click here to exclude patents covering these drugs from this list
Applicant | Tradename | Generic Name | NDA | Approval Date | Type | Patent No. | Patent Expiration | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|
Astellas | CRESEMBA | isavuconazonium sulfate | 207500 | Nov 22, 2022 | RX | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | PEDIATRIC EXCLUSIVITY |
Astellas | CRESEMBA | isavuconazonium sulfate | 207500 | Nov 22, 2022 | RX | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | PEDIATRIC EXCLUSIVITY |
Astellas | CRESEMBA | isavuconazonium sulfate | 207500 | Nov 22, 2022 | RX | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | PEDIATRIC EXCLUSIVITY |
Astellas | CRESEMBA | isavuconazonium sulfate | 207500 | Nov 22, 2022 | RX | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | PEDIATRIC EXCLUSIVITY |
>Applicant | >Tradename | >Generic Name | >NDA | >Approval Date | >Type | >Patent No. | >Patent Expiration | >Exclusivity Expiration | >Patented / Exclusive Use |